Click here to get this post in PDF
Dr. Alaa Salem entered healthcare with a dream to heal one patient at a time. He moved quickly through his education, finishing college in three years and taking the traditional pre-med path all the way to medical school overseas. But along the way, he came to understand that the best care he could offer was worthless if people couldn’t reach it or afford it long enough to benefit from it.
That insight pulled him deeper into medicine at the system level, which eventually led him to build Metabolic Supply Group (MSG). This public-health-driven network strengthens independent providers and expands patient access in an industry often distracted by price and speed.
As Dr. Salem puts it, “A treatment’s quality means very little if patients can’t access it. We must ensure that they fully understand the treatment and can remain engaged long enough to receive all of its benefits.”
Dr. Alaa Salem moves from pre-med to choose the bigger battlefield
Dr. Salem first obtained a Master of Science in Clinical Research Administration and an MBA in Healthcare Management. He then went on to earn a doctorate focused on healthcare and population health management. That move to public health would enable him to solve problems that clinical skill alone could not fix.
“I realized I was less drawn to practicing medicine in a traditional sense and more compelled by the structures surrounding the patient,” Dr. Salem recalls. “That included the hidden obstacles and inequities I commonly saw in access. Those details impact people’s lives every day.”
Where Dr. Alaa Salem learned what today’s patients need
At NYU Langone, Dr. Salem worked in oncology patient navigation. There, he saw healthcare in its rawest form.
In cancer care, time is critical, and confusion is costly. Barriers such as emotional overwhelm or language gaps can snowball quickly. Missed appointments and insurance complexity make the situation continuously worse.
Dr. Salem watched patients try to do everything and quickly learned that a patient’s treatment is far more than chemotherapy or surgery. It also includes all of the phone calls, rides, coordination, translation, and human support that help a person keep going.
“Treatment doesn’t happen in isolation,” Dr. Salem reflects. “Today, whenever I evaluate a healthcare model, I always ask if it supports the whole journey, or only the transaction.”
Then came Weill Cornell Medicine, where Dr. Salem helped oversee the National Institutes of Health’s All of Us Research Program. This effort gathered health data from more than 1 million people with the goal of advancing precision medicine. The work reinforced his belief that the future of healthcare must be individualized and data-informed.
“Healthcare must become more responsive,” Dr. Salem explains. “The way we personalize treatment can’t end when we write a prescription. It must include how we help each patient trust our care plan and stick with it.”
How Dr. Alaa Salem’s clinical research expanded access where options were most limited
Dr. Salem later moved into clinical research operations, where he oversaw more than 100 research sites throughout Florida, focusing on complex conditions like Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and dementia. These diagnoses often come with fear surrounding limited treatments and few clear answers, creating the kind of environment for patients where clinical research is a lifeline. By helping physician practices integrate clinical research into patient care, he was working to bring more opportunities to people who otherwise wouldn’t get them.
Looking back across his career, Dr. Salem sees a unified mission.
“I have always worked to remove barriers and expand access,” he says. “My goal has always been to connect patients with better opportunities for care.”
A pharmacy distribution network in the supply chain
In 2023, a close friend invited Dr. Salem to help build a newly licensed compounding pharmacy, where Dr. Salem saw the troubling trends facing independent medical practices. These clinics were being squeezed by massive national telehealth brands with enormous ad budgets. Meanwhile, industry conversations were increasingly dominated by what clinics could charge and what margin they could keep.
“Questions about quality, compliance, protocols, patient experience, and long-term outcomes often took second place to questions about cost per milligram,” Dr. Salem recalls. “Our industry clearly needed a new model that could create purchasing power without becoming transactional, and support independent providers without sacrificing standards.”
That belief became MSG, a network that would offer competitive pricing paired with reliable pharmacy relationships and clinical resources. Its mission is to translate savings directly into stronger care.
“When MSG helps a practice lower its costs,” Dr. Salem says, “those savings can create value beyond a larger profit margin.”
With its first 44 clients, MSG generated about 400,000 dollars in monthly revenue. Providers responded to the purpose, so much so that in January 2026, Dr. Salem exited pharmacy ownership and committed to building MSG full-time.
The healthcare industry supply chain that MSG is building
Today, MSG supports hundreds of practices nationwide, but Dr. Salem’s vision goes beyond improving how practices purchase compounded medications. MSG is expanding into healthcare infrastructure that offers biomarker testing for more informed care and a Metabolic Research Network to link research opportunities with motivated patient populations. The company is also offering stronger transparency expectations around quality, sourcing, shipping, and testing.
“For me, this isn’t simply about supplying products,” Dr. Alaa Salem says. “It’s about establishing greater accountability in an industry that has grown faster than many of the systems surrounding it. Instead of caring for one patient at a time, we’re building the systems that help thousands of providers take better care of hundreds of thousands of patients.”
You may also like: Why Patients Should Shape Drug Development Long Before Approval, According to Leen Kawas
Image source: Magnific.com
